Quantitative Analysis of Macrophage Inhibitory Cytokine-1 (MIC-1) Gene Expression in Human Prostatic Tissues

Overview

Journal Br J Cancer

Specialty Oncology

Date 2003 Apr 3

PMID 12671711

Citations 30

Authors

T Nakamura

A Scorilas

C Stephan

G M Yousef

G Kristiansen

K Jung

E P Diamandis

Affiliations

Soon will be listed here.

Abstract

Macrophage inhibitory cytokine-1 (MIC-1) gene is a member of transforming growth factor-beta superfamily and was reported to be highly overexpressed in human prostate cancer using microarray technology. The aim of this study was to evaluate the quantitative expression of MIC-1 in malignant and benign prostate tissues and to associate expression levels with clinicopathological parameters of prostate cancer. Matched (paired) prostatic tissue samples from the cancerous and noncancerous parts of the same prostates were obtained from 66 patients who underwent radical prostatectomy. Quantitative RT-PCR was performed using SYBR Green I on the Roche LightCycler system. Macrophage inhibitory cytokine-1 gene overexpression in cancerous tissues was observed in 88% of cases, compared to noncancerous tissues (P<0.001). The expression level of MIC-1 in cancerous tissues was significantly higher than in noncancerous tissue (P<0.001). Higher expression of MIC-1 gene was significantly associated with higher Gleason score (P=0.004). The expression of the MIC-1 gene in prostate cancer is significantly higher than in noncancerous tissues, especially in more aggressive forms of the disease (Gleason score>5). This is in contrast to prostate-specific antigen that is downregulated in higher-grade tumours. The upregulation of MIC-1 in prostate cancer and in advanced and more aggressive prostatic tumours suggests that MIC-1 protein should be evaluated as a potential diagnostic and prognostic biomarker.

Citing Articles

Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia.

Bonaterra G, Schleper A, Skowronek M, Kilian L, Rink T, Schwarzbach H Cancers (Basel). 2022; 14(19).

PMID: 36230513 PMC: 9578283. DOI: 10.3390/cancers14194591.

NR5A2 transcriptional activation by BRD4 promotes pancreatic cancer progression by upregulating GDF15.

Guo F, Zhou Y, Guo H, Ren D, Jin X, Wu H Cell Death Discov. 2021; 7(1):78.

PMID: 33850096 PMC: 8044179. DOI: 10.1038/s41420-021-00462-8.

Cardiac Endocrinology: Heart-Derived Hormones in Physiology and Disease.

Zhao J, Pei L JACC Basic Transl Sci. 2020; 5(9):949-960.

PMID: 33015416 PMC: 7524786. DOI: 10.1016/j.jacbts.2020.05.007.

The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.

Sadasivan S, Chen Y, Gupta N, Han X, Bobbitt K, Chitale D Carcinogenesis. 2020; 41(8):1074-1082.

PMID: 32614434 PMC: 7422623. DOI: 10.1093/carcin/bgaa065.

Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases.

Baek S, Eling T Pharmacol Ther. 2019; 198:46-58.

PMID: 30790643 PMC: 7196666. DOI: 10.1016/j.pharmthera.2019.02.008.

References

Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L . PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta. 1997; 1354(1):40-4. DOI: 10.1016/s0167-4781(97)00122-x. View

Bilhartz D, Tindall D, Oesterling J . Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. Urology. 1991; 38(2):95-102. DOI: 10.1016/s0090-4295(05)80066-4. View

Wittwer C, Herrmann M, Moss A, Rasmussen R . Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 1997; 22(1):130-1, 134-8. DOI: 10.2144/97221bi01. View

Diamandis E, Yousef G, Luo L, Magklara A, Obiezu C . The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab. 2000; 11(2):54-60. DOI: 10.1016/s1043-2760(99)00225-8. View

Stephan C, Jung K, Diamandis E, Rittenhouse H, Lein M, Loening S . Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology. 2002; 59(1):2-8. DOI: 10.1016/s0090-4295(01)01449-2. View

Rittenhouse H, Finlay J, Mikolajczyk S, Partin A . Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 1998; 35(4):275-368. DOI: 10.1080/10408369891234219. View

Oesterling J . Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991; 145(5):907-23. DOI: 10.1016/s0022-5347(17)38491-4. View

Thomas R, True L, Lange P, Vessella R . Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer. 2001; 93(1):47-52. DOI: 10.1002/ijc.1291. View

Buckhaults P, Rago C, St Croix B, Romans K, Saha S, Zhang L . Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res. 2001; 61(19):6996-7001. View

10.

Bottner M, Suter-Crazzolara C, Schober A, Unsicker K . Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res. 1999; 297(1):103-10. DOI: 10.1007/s004410051337. View

11.

Bootcov M, Bauskin A, Valenzuela S, Moore A, Bansal M, He X . MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997; 94(21):11514-9. PMC: 23523. DOI: 10.1073/pnas.94.21.11514. View

12.

Pepe M, Etzioni R, Feng Z, Potter J, Thompson M, Thornquist M . Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-61. DOI: 10.1093/jnci/93.14.1054. View

13.

Diamandis E, Yousef G, Clements J, Ashworth L, Yoshida S, Egelrud T . New nomenclature for the human tissue kallikrein gene family. Clin Chem. 2000; 46(11):1855-8. View

14.

Mitchell I, Croal B, DICKIE A, Cohen N, Ross I . A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol. 2001; 165(5):1549-53. View

15.

Welsh J, Sapinoso L, Su A, Kern S, Wang-Rodriguez J, Moskaluk C . Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001; 61(16):5974-8. View

16.

Meyer-Siegler K, Bellino M, Tannenbaum M . Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 2002; 94(5):1449-56. DOI: 10.1002/cncr.10354. View

17.

Stamey T . Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem. 2001; 47(4):631-4. View

18.

Polascik T, Oesterling J, Partin A . Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999; 162(2):293-306. DOI: 10.1016/s0022-5347(05)68543-6. View

19.

Wong Y, Xie W, Tsao S . Structural changes and alteration in expression of TGF-beta1 and its receptors in prostatic intraepithelial neoplasia (PIN) in the ventral prostate of noble rats. Prostate. 2000; 45(4):289-98. DOI: 10.1002/1097-0045(20001201)45:4<289::aid-pros2>3.0.co;2-o. View

20.

Bieche I, Olivi M, Champeme M, Vidaud D, Lidereau R, Vidaud M . Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer. 1998; 78(5):661-6. DOI: 10.1002/(sici)1097-0215(19981123)78:5<661::aid-ijc22>3.0.co;2-i. View